147 related articles for article (PubMed ID: 21740461)
1. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
Fukuhara S; Watanabe T; Munakata W; Mori M; Maruyama D; Kim SW; Kobayashi Y; Taniguchi H; Maeshima AM; Tanosaki R; Matsuno Y; Tobinai K
Eur J Haematol; 2011 Nov; 87(5):434-40. PubMed ID: 21740461
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
[TBL] [Abstract][Full Text] [Related]
4. [Primary breast lymphoma--a report of 27 cases with literature review].
Cao YB; Wang SS; Huang HQ; Xu GC; He YJ; Guan ZZ; Lin TY
Ai Zheng; 2007 Jan; 26(1):84-9. PubMed ID: 17222374
[TBL] [Abstract][Full Text] [Related]
5. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
Seker M; Bilici A; Ustaalioglu BO; Yilmaz B; Ozturk B; Ünal A; Dane F; Ozdemir NY; Elkiran ET; Kalender ME; Gumus M; Benekli M
Arch Gynecol Obstet; 2011 Aug; 284(2):405-9. PubMed ID: 20872226
[TBL] [Abstract][Full Text] [Related]
7. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy.
McClanahan F; Hielscher T; Rieger M; Hensel M; Neben K; Hillengass J; Herfarth K; Ho AD; Witzens-Harig M
Eur J Haematol; 2010 Jul; 85(1):11-9. PubMed ID: 20331739
[TBL] [Abstract][Full Text] [Related]
9. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
10. Non-Hodgkin lymphoma of the breast.
Ganjoo K; Advani R; Mariappan MR; McMillan A; Horning S
Cancer; 2007 Jul; 110(1):25-30. PubMed ID: 17541937
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and pathological analysis of 15 cases with primary breast lymphoma].
Huang DZ; He XH; Yang S; Shi YK
Ai Zheng; 2004 Aug; 23(8):939-42. PubMed ID: 15301719
[TBL] [Abstract][Full Text] [Related]
12. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.
Oprea C; Cainap C; Azoulay R; Assaf E; Jabbour E; Koscielny S; Lapusan S; Vanel D; Bosq J; Ribrag V
Br J Haematol; 2005 Nov; 131(4):468-71. PubMed ID: 16281936
[TBL] [Abstract][Full Text] [Related]
13. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
[TBL] [Abstract][Full Text] [Related]
14. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.
Tomita N; Yokoyama M; Yamamoto W; Watanabe R; Shimazu Y; Masaki Y; Tsunoda S; Hashimoto C; Murayama K; Yano T; Okamoto R; Kikuchi A; Tamura K; Sato K; Sunami K; Shibayama H; Takimoto R; Ohshima R; Hatta Y; Moriuchi Y; Kinoshita T; Yamamoto M; Numata A; Ishigatsubo Y; Takeuchi K
Cancer Sci; 2012 Feb; 103(2):245-51. PubMed ID: 22044593
[TBL] [Abstract][Full Text] [Related]
17. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic features of primary thyroid lymphoma].
Zhou SY; Huang DZ; Shi YK; He XH; Wu YH; Li YX
Ai Zheng; 2005 Jan; 24(1):95-8. PubMed ID: 15642210
[TBL] [Abstract][Full Text] [Related]
19. Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy.
Choo SP; Lim ST; Wong EH; Tao M
Onkologie; 2006 Feb; 29(1-2):14-8. PubMed ID: 16514249
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
